Axovia Therapeutics at Cell 2026

Nov 12–13, 2026 London, UK ~800 attendees Website

Axovia Therapeutics takes part in 2 sessions at Cell 2026 in London, its home city. Its sessions centre on gene therapy for genetic sight loss and on where advanced therapies are heading in science, clinics, regulation and economics. It describes a clinical trial of gene therapy aimed at halting retinal degeneration in Bardet-Biedl syndrome.

OrganizationCell 2026 Attendance
axoviatherapeutics.com
Biotech
Develops gene therapies for genetic forms of obesity and ciliopathies, including Bardet-Biedl syndrome.
Talk
Thu Nov 12
10:15am–10:40am
The Development Of The AXIS Trial. Gene Therapy To Halt The Retinal Degeneration In Bardet-Biedl Syndrome
Cell and gene therapy
Panel
Thu Nov 12
3:05pm–3:30pm
Where Advanced Therapies Will Be In 2030: Scientific, Clinical, Regulatory & Economic Futures
with NextCell Pharma, BioNTech
Cell and gene therapy

Explore the full Cell 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in London. Leave your work email and we’ll be in touch.

Privacy

Download the full Cell 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Axovia Therapeutics

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by Cell 2026 or its organizers. Submit a correction